Compare PCRX & KRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | KRUS |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 869.6M |
| IPO Year | 2010 | 2019 |
| Metric | PCRX | KRUS |
|---|---|---|
| Price | $22.83 | $59.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $35.33 | ★ $81.50 |
| AVG Volume (30 Days) | ★ 736.7K | 190.4K |
| Earning Date | 01-01-0001 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | 79.75 |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $541,533,000.00 | $282,763,000.00 |
| Revenue This Year | $9.77 | $21.66 |
| Revenue Next Year | $9.71 | $17.89 |
| P/E Ratio | $140.38 | ★ N/A |
| Revenue Growth | ★ 26.04 | 18.88 |
| 52 Week Low | $18.80 | $40.07 |
| 52 Week High | $27.99 | $95.98 |
| Indicator | PCRX | KRUS |
|---|---|---|
| Relative Strength Index (RSI) | 52.95 | 35.58 |
| Support Level | $20.41 | $55.30 |
| Resistance Level | $23.82 | $69.06 |
| Average True Range (ATR) | 1.01 | 3.89 |
| MACD | 0.02 | -1.54 |
| Stochastic Oscillator | 68.81 | 17.77 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.